Opus Genetics Set to Engage at H.C. Wainwright Conference
Opus Genetics, Inc. (Nasdaq: IRD), a cutting-edge clinical-stage biopharmaceutical company, is excited to announce its participation at the prestigious H.C. Wainwright 27th Annual Global Investment Conference. Scheduled for September 8-10, 2025, this event represents an opportunity for the company to provide an insightful update about its ongoing progress in developing transformative gene therapies.
Spotlight on Innovative Presentations
George Magrath, MD, the Chief Executive Officer of Opus Genetics, along with Ash Jayagopal, Ph.D., MBA, the Chief Scientific and Development Officer, will present a corporate update that highlights significant advancements and future directions. The presentation will be available on demand starting September 8, 2025, at 7:00 a.m. ET, allowing investors and stakeholders to stay informed about the company’s trajectory.
Recent Investor Engagements
In addition to the upcoming conference, Opus Genetics has provision for replays from other recent investor engagements. These include:
- Nasdaq Spotlight interview
- Chardan Virtual Ophthalmology Summit Series, featuring discussions on rare ophthalmic diseases
- Jones Trading's Virtual Presbyopia Expert Panel
Accessing Replay Opportunities
Interested parties can find access to these webcasts under the Investor section of the Opus Genetics website. Engaging with these materials can provide valuable insights into the company's strategy and developments in the field of ophthalmology.
Unpacking the Mission of Opus Genetics
At its core, Opus Genetics is dedicated to tackling inherited retinal diseases (IRDs) through groundbreaking innovations. Their pipeline bravery features AAV-based gene therapies specifically aimed at addressing critical conditions like Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. These conditions make everyday activities challenging for those affected, and the therapies developed by Opus Genetics promise to change lives.
Leading the Charge
The lead gene therapy candidates of Opus Genetics include OPGx-LCA5, currently undergoing an ongoing Phase 1/2 trial targeting LCA5-related mutations. Additionally, they are advancing OPGx-BEST1, which is engineered to tackle BEST1-related retinal degeneration. These innovative solutions are on the forefront of genetic medicine in ophthalmology.
Expanding Treatment Horizons
Moreover, Opus Genetics is also making strides in the development of Phentolamine Ophthalmic Solution 0.75%. This partnered therapy is already approved for certain indications and is currently undergoing two Phase 3 programs aimed at addressing presbyopia, as well as enhancing visual function in low light and nighttime conditions. The potential impact of these advancements on individuals' lives cannot be overstated.
Commitment to Excellence
Based in Research Triangle Park, NC, Opus Genetics remains committed to providing innovative solutions for ophthalmic disorders. Their work not only represents scientific progress but also the hope for those who struggle with these debilitating conditions. For any further information, including details about ongoing trials and the corporate strategy, you can visit the official Opus Genetics website.
Frequently Asked Questions
What is Opus Genetics focusing on at the conference?
Opus Genetics will present a corporate update about their advancements in gene therapies for inherited retinal diseases.
When is the presentation available for viewing?
The presentation will be available on demand on September 8, 2025, at 7:00 a.m. ET.
What are some recent programs by Opus Genetics?
Recent programs include the Nasdaq Spotlight interview and discussions on rare ophthalmic diseases in virtual summits.
What are the main therapies being developed by Opus Genetics?
Opus Genetics is developing gene therapies targeting LCA, bestrophinopathy, retinitis pigmentosa, and a treatment for presbyopia.
Where is Opus Genetics located?
The company is based in Research Triangle Park, North Carolina.